{"id":"W2103257412","doi":"10.1200/jco.2005.07.757","title":"Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinblastine; Gemcitabine; Internal medicine; Transitional cell carcinoma; Hazard ratio; Cisplatin; Bladder cancer; Urology; Oncology; Methotrexate; Chemotherapy; Doxorubicin; Antimetabolite; Progression-free survival; Gastroenterology; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08192046514609955,"score_gpt":0.4237490158951968,"score_spread":0.3418285507490972,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}